List – 30 Drug Patents that are Expiring in 2028
Our list of patents expiring from 2021 to 2025 was a blockbuster in the generic drug market.
With the huge growth in the generic drug market, there is no doubt that generic companies (you too?) are searching for drugs with a soon-to-be-expired label. So we decided to up our game further and extract all the drug patents expiring in this decade. So far we have published the drug patents expiring in 2026 and 2027. And today, I come bearing the list of drugs going off-patent in 2028.
To make their (your) work easy, we collected not just the drug names, but also included other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version.
Without any delay, here is the list of drugs. Thank us later!
The article has a list of drug patents expiring in 2028. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Drug Patents Expiring in 2028
Mutamycin
Mitomycin
Mitomycin
| Patents | Expiration Date |
|---|---|
| US9539241 | January 2, 2028 |
Dosage: Intravenous Powder For Injection
Company: Biochem Pharmaceutical Industries
Ingredients: MITOMYCIN
Treatment: Upper Gastro-intestinal Cancers, Anal Cancers, and Breast Cancers
Farydak
Panobinostat
Panobinostat
| Patents | Expiration Date |
|---|---|
| US7989494 | January 17, 2028 |
Dosage: Oral
Company: Secura Bio
Ingredients: PANOBINOSTAT LACTATE
Treatment: Various Cancers
Sivextro
Tedizolid
Tedizolid
| Patents | Expiration Date |
|---|---|
| US8420676 | February 23, 2028 |
| US7816379 | June 20, 2028 |
| US9624250 | February 3, 2030 |
| US9624250 | February 3, 2030 |
| US8426389 | December 31, 2030 |
Dosage: Oral, Intravenous
Company: Cubist Pharmaceuticals
Ingredients: TEDIZOLID PHOSPHATE
Treatment: Complicated Skin And Skin-structure Infections (CSSSIS)
Xenleta
Lefamulin
Lefamulin
| Patents | Expiration Date |
|---|---|
| US8153689 | March 19, 2028 |
| US8071643 | January 16, 2029 |
| US9120727 | May 23, 2031 |
Dosage: Oral, Intravenous
Company: Nabriva Therapeutics
Ingredients: LEFAMULIN ACETATE
Treatment: Pneumonia
Vosevi
Sofosbuvir/Velpatasvir/Voxilaprevir
Sofosbuvir/Velpatasvir/Voxilaprevir
| Patents | Expiration Date |
|---|---|
| US9585906 | March 21, 2028 |
| US8735372 | September 21, 2028 |
| US8889159 | September 26, 2029 |
| US9868745 | November 16, 2032 |
| US9296782 | July 17, 2034 |
Dosage: Oral
Company: Gilead Sciences
Ingredients: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
Treatment: Hepatitis C
Zerbaxa
Ceftolozane/Tazobactam
Ceftolozane/Tazobactam
| Patents | Expiration Date |
|---|---|
| US7129232 | May 15, 2028 |
| US8685957 | September 27, 2032 |
| US8476425 | September 27, 2032 |
| US8906898 | May 28, 2034 |
Dosage: Intravenous
Company: Merck & Co
Ingredients: CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM
Treatment: Urinary Tract Infections
Kybella
Deoxycholic Acid
Deoxycholic Acid
| Patents | Expiration Date |
|---|---|
| US8242294 | May 16, 2028 |
Dosage: Injections
Company: Kythera Biopharmaceuticals Inc
Ingredients: DEOXYCHOLIC ACID
Treatment: Double Chin
Tepmetko
Tepotinib
Tepotinib
| Patents | Expiration Date |
|---|---|
| US8921357 | May 30, 2028 |
| US8329692 | October 30, 2029 |
| US8580781 | March 19, 2030 |
Dosage: Oral
Company: Emd Serono Inc
Ingredients: TEPOTINIB HYDROCHLORIDE
Treatment: Non-small Cell Lung Cancer (NSCLC)
Kisqali
Ribociclib
Ribociclib
| Patents | Expiration Date |
|---|---|
| US8324225 | June 17, 2028 |
| US8415355 | August 21, 2029 |
| US8685980 | May 25, 2030 |
| US9193732 | November 9, 2031 |
Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: RIBOCICLIB SUCCINATE
Treatment: Breast Cancer
Osmoprep
Sodium Phosphate Monobasic Monohydrate And Sodium Phosphate Dibasic Anhydrous
Sodium Phosphate Monobasic Monohydrate And Sodium Phosphate Dibasic Anhydrous
| Patents | Expiration Date |
|---|---|
| US7687075 | June 22, 2028 |
Dosage: Oral
Company: Salix Pharmaceuticals Inc
Ingredients: SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Treatment: Constipation
Rozlytrek
Entrectinib
Entrectinib
| Patents | Expiration Date |
|---|---|
| US9029356 | July 8, 2028 |
| US8299057 | March 1, 2029 |
| US9085565 | May 22, 2033 |
| US10738037 | May 18, 2037 |
Dosage: Oral
Company: Genentech Inc
Ingredients: ENTRECTINIB
Treatment: Non-small Cell Lung Cancer
Minivelle
Estradiol
Estradiol
| Patents | Expiration Date |
|---|---|
| US9724310 | July 10, 2028 |
| US8231906 | July 4, 2030 |
Dosage: Transdermal
Company: Noven Pharmaceuticals Inc
Ingredients: ESTRADIOL
Treatment: Menopause
Truseltiq
Infigratinib
Infigratinib
| Patents | Expiration Date |
|---|---|
| US9067896 | August 6, 2028 |
| US8552002 | August 25, 2029 |
Dosage: Oral
Company: Helsinn Healthcare Sa
Ingredients: INFIGRATINIB PHOSPHATE
Treatment: Cholangiocarcinoma
Syndros
Dronabinol
Dronabinol
| Patents | Expiration Date |
|---|---|
| US9345771 | August 6, 2028 |
| US8222292 | August 6, 2028 |
| US10265293 | August 6, 2028 |
| US11253472 | August 6, 2028 |
Dosage: Oral
Company: Benuvia Therapeutics Inc
Ingredients: DRONABINOL
Treatment: Nausea And Vomiting Caused By Chemotherapy
Vizimpro
Dacomitinib
Dacomitinib
| Patents | Expiration Date |
|---|---|
| US7772243 | August 26, 2028 |
Dosage: Oral
Company: Pfizer Inc
Ingredients: DACOMITINIB
Treatment: Non-small Cell Lung Cancer (NSCLC)
Viekira Pak
Ombitasvir/Paritaprevir/Ritonavir
Ombitasvir/Paritaprevir/Ritonavir
| Patents | Expiration Date |
|---|---|
| US8501238 | September 17, 2028 |
| US8188104 | May 17, 2029 |
| US8642538 | September 10, 2029 |
| US8420596 | April 10, 2031 |
| US8691938 | April 13, 2032 |
Dosage: Oral
Company: Abbvie Inc
Ingredients: DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
Treatment: Hepatitis C
Epclusa
Sofosbuvir/Velpatasvir
Sofosbuvir/Velpatasvir
| Patents | Expiration Date |
|---|---|
| US8580765 | September 21, 2028 |
| US8334270 | September 21, 2028 |
| US9085573 | September 21, 2028 |
| US7964580 | September 26, 2029 |
| US8633309 | September 26, 2029 |
| US9284342 | March 13, 2031 |
| US8618076 | June 11, 2031 |
| US8575135 | May 16, 2033 |
| US8921341 | May 16, 2033 |
| US8940718 | May 16, 2033 |
Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: SOFOSBUVIR; VELPATASVIR
Treatment: Hepatitis C
Inqovi
Decitabine/Cedazuridine
Decitabine/Cedazuridine
| Patents | Expiration Date |
|---|---|
| US9567363 | October 16, 2028 |
| US8268800 | August 22, 2030 |
Dosage: Oral
Company: Otsuka Pharmaceutical Co Ltd
Ingredients: CEDAZURIDINE; DECITABINE
Treatment: Myelodysplastic Syndromes (MDS) And Chronic Myelomonocytic Leukemia (CMML)
Erivedge
Vismodegib
Vismodegib
| Patents | Expiration Date |
|---|---|
| US7888364 | November 11, 2028 |
Dosage: Oral
Company: Genentech Inc
Ingredients: VISMODEGIB
Treatment: Basal-cell Carcinoma (BCC)
Zemdri
Plazomicin
Plazomicin
| Patents | Expiration Date |
|---|---|
| US9688711 | November 21, 2028 |
| US8383596 | June 2, 2031 |
Dosage: Intravenous
Company: Cipla USA Inc
Ingredients: PLAZOMICIN SULFATE
Treatment: Urinary Tract Infections
Remodulin
Treprostinil
Treprostinil
| Patents | Expiration Date |
|---|---|
| US9604901 | December 15, 2028 |
| US9593066 | December 15, 2028 |
Dosage: Intravenous, Subcutaneous
Company: United Therapeutics Corp
Ingredients: TREPROSTINIL
Treatment: Pulmonary Arterial Hypertension
Vraylar
Cariprazine
Cariprazine
| Patents | Expiration Date |
|---|---|
| US7943621 | December 16, 2028 |
| US7737142 | September 17, 2029 |
Dosage: Oral
Company: Allergan
Ingredients: CARIPRAZINE HYDROCHLORIDE
Treatment: Schizophrenia, Bipolar Mania, and Bipolar Depression
If you reached here, you are definitely looking for more! We know you, cos we are you. Just like you, we try to stay a step ahead of our competitors too. And so, our pharma team is working on its toes to extract all the drug patents expiring in the next 8 years from now. Want to get your hands on the complete list?
